Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) said today it entered into an agreement to acquire Unilens Vision for $28 million, including $5 million in debt. Under the agreement, which was unanimously approved by Largo, Fla.-based Unilens’ board of directors, a wholly-owned subsidiary of Valeant will acquire Unilens for $12.75 per share in cash. “We are very pleased […]
HeartWare International (NSDQ:HTWR) reported strong sales growth amid widening losses for the 4th quarter and 2011, and Wall Street showed some love.
The Framingham, Mass.-based heart pump maker raked in $82.8 million for the year ended Dec. 31, 2011, a 50% bump from $55.2 million in 2010. Losses, however, widened to $55.1 million, or $3.94 per diluted share. Analysts had forecast a loss of $3.17 per diluted share for 2011.